BioMed X Launches Women's Health R&D Accelerator with Gates Foundation Support
BioMed X has launched XFem Labs, a women's health research accelerator in Heidelberg focused on developing non-hormonal contraceptive solutions to address global access barriers and high discontinuation rates of current methods.
BioMed X announced the launch of XFem Labs, a new Women's Health R&D Accelerator in Heidelberg supported by the Gates Foundation. The initiative aims to establish a world-class women's health innovation hub that advances early-stage research into scalable solutions for women worldwide, including those in low- and middle-income countries. The accelerator represents a significant step toward addressing critical gaps in women's healthcare through targeted research and development.
The first project at XFem Labs focuses on developing new strategies for female-controlled non-hormonal contraception. Despite various contraceptive options being available, 257 million women globally face significant access barriers. Current hormonal contraceptives often cause side effects like changes in bleeding patterns, leading to high discontinuation rates. The limited availability of non-hormonal, female-controlled alternatives creates an urgent need for new options that could improve women's reproductive health outcomes globally.
Embedded within the academic environments of the University of Heidelberg and Yale, and directly within R&D campuses of leading pharmaceutical companies, BioMed X bridges the translational gap between academia and industry to drive transformative innovation. This strategic positioning allows the accelerator to leverage academic research excellence while maintaining industry relevance for practical application.
The first XFem Labs call for applications invites proposals exploring new biological targets, molecular mechanisms, or delivery modalities for continuous and on-demand non-hormonal contraception. Selected researchers will participate in a boot camp at BioMed X, resulting in the incubation of a new research team based in Heidelberg. Researchers interested in joining this initiative can submit project proposals through the BioMed X Career Space before December 7, 2025.
Dr. Christian Tidona, CEO of BioMed X, emphasized the collaborative nature of the project, stating that their joint goal with the Gates Foundation is to create significant impact on women's lives and health worldwide. The initiative will work with an international network of top experts and key opinion leaders to build and mentor new research teams addressing pressing women's health challenges. The first XFem Labs project is supported by a $2 million grant and network support from the Gates Foundation, underscoring the importance of developing accessible, effective contraceptive options for women across different economic backgrounds and geographic regions.